




RealRate

PHARMACEUTICAL 2021

Keenova Therapeutics plc
Rank 304 of 394



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Keenova Therapeutics plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Keenova Therapeutics plc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 36% points. The greatest weakness of Keenova Therapeutics plc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 119% points.

The company's Economic Capital Ratio, given in the ranking table, is 149%, being 107% points below the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	2,304,300
Cost of Goods Sold	1,544,000
Intangible Assets	6,184,500
Liabilities, Current	4,118,700
Liabilities, Non-Current	109,800
Other Assets	393,500
Other Compr. Net Income	-1,700
Other Expenses	1,030,100
Other Liabilities	4,467,700
Other Net Income	55,000
Other Revenues	2,213,400
Property and Equipment	833,100
Research and Development	290,800
Selling, General and Administrative Expense	884,100

Output Variable	Value in 1000 USD
Assets	9,715,400
Liabilities	8,696,200
Expenses	3,749,000
Revenues	2,213,400
Stockholders Equity	1,019,200
Net Income	-1,480,600
Comprehensive Net Income	-1,481,450
BaseVar	12,215,350
ECR before Limited Liability	8.0%
Economic Capital Ratio	149%